17:58 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

FDA places hold on upcoming Phase I for point-of-care CAR Ts

FDA placed a clinical hold on an upcoming Phase I trial sponsored by Ziopharm Oncology Inc. (NASDAQ:ZIOP), which would be the first for its third-generation, point-of-care CAR T cells that require two days for manufacturing....
23:50 , Jun 18, 2018 |  BC Extra  |  Clinical News

Hold for upcoming point-of-care CAR T trial sinks Ziopharm shares

FDA placed a clinical hold on an upcoming Phase I trial sponsored by Ziopharm Oncology Inc. (NASDAQ:ZIOP), which would be the first for its third-generation, point-of-care CAR T cells that require two days for manufacturing....
07:00 , Apr 21, 2014 |  BioCentury  |  Product Development

CAR hits pothole

Patient deaths prompted Memorial Sloan Kettering Cancer Center to briefly halt enrollment and update inclusion criteria for its CD19 directed chimeric antigen receptor T cell therapy. But partner Juno Therapeutics Inc. and other CAR players...